Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has shown significant improvement in progression-free survival compared to chemotherapy in clinical trials. This partnership aims to enhance patient access and support for this targeted cancer therapy across the U.S.
AstraZeneca (AZN) shares are trading at USD 171.71 on Pluang as of Oct 27, 2026 04:12 WIB, which is closer to its 52-week low of USD 155.62 than its high of USD 209.48. Despite the recent partnership news, the stock's 1-day change is modest at +0.13%. Investors on Pluang show strong buying interest with 96% of order activity as buys, reflecting confidence in the health sector stock amid its current price range.
AstraZeneca will report its Q3 2026 earnings on October 30, facing pressure from generic competition on its cardiology drug Farxiga and a failed cardiology trial. However, strong oncology sales, led by Imfinzi and Enhertu, have driven overall revenue...
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
AstraZeneca remains a strong long-term Buy due to its robust product lineup and promising pipeline, aiming for $80 billion in revenues by 2030. The company currently has 14 blockbuster drugs and expects up to 12 more from its pipeline by decade's end...
